Clinical Trial News Archive - January 2024
January 2, 2024
- Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
- Anavex Life Sciences Provides an Update on ANAVEX®2-73 Rett Syndrome Program
January 3, 2024
- First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx System for Administration of Spinraza
- Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis
- New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
January 4, 2024
- AskBio Phase Ib Trial of AB-1005 Gene Therapy in Patients with Parkinson’s Disease Meets Primary Endpoint
- Lapatinib Increases Overall Survival in Metastatic Breast Cancer Patients With HER2-Positive Circulating Tumor Cells
January 5, 2024
- Semaglutide Associated with Lower Risk of Suicidal Ideations Compared to Other Treatments Prescribed for Obesity or Type 2 Diabetes
- Oryzon Announces Topline Results from Phase IIb PORTICO study of Vafidemstat in Borderline Personality Disorder (BPD)
January 8, 2024
- FDA Approves Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
- Lutikizumab Showed Positive Results in a Phase 2 Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase 3
- Residential Addiction Treatment for Adolescents is Scarce and Expensive
- Bayer’s Elinzanetant Meets All Primary and Key Secondary Endpoints in Pivotal OASIS 1 and 2 Phase III Studies
- Bayer Starts Phase II Study NIRVANA to Evaluate Elinzanetant in Women with Sleep Disturbances Associated with Menopause
January 9, 2024
- A Common Marker of Neurological Diseases May Play Role in Healthy Brains
- Marius Pharmaceuticals Announces Pilot Study Exploring the Effect of Its Oral Testosterone Therapy, KYZATREX on Male Fertility
January 10, 2024
- Reduced Drug Use is a Meaningful Treatment Outcome for People with Stimulant Use Disorders
- Open Enrollment Commences for Phase 1b/2 Study Evaluating Ampligen in Combination with Imfinzi for the Treatment of Pancreatic Cancer
January 11, 2024
- Reduced Blood Lead Levels Linked to Lower Blood Pressure in American Indians
- Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure (CHF)
January 14, 2024
- New Prostate Cancer Foundation-Funded Research To Speed Up Prostate Cancer Clinical Trials Worldwide
January 16, 2024
- Pleco Therapeutics receives FDA Orphan Drug Designation for PTX-252
- NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis
- Atsena Therapeutics Receives Rare Pediatric Disease Designation from FDA for ATSN-101 Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis (LCA1)
January 17, 2024
January 18, 2024
- Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody
- Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
- Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01
January 19, 2024
January 23, 2024
- Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting
- Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR
January 25, 2024
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
- FDA Agrees to Amend Special Protocol Assessment for Clinical Trial of AXPAXLI in Wet AMD
January 26, 2024
January 28, 2024
January 29, 2024
January 30, 2024
- FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
- Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
- Switching to Vegan or Ketogenic Diet Rapidly Impacts Immune System
January 31, 2024
- NIH Analysis Reveals a Significant Rise in Use of Complementary Health Approaches, Especially for Pain Management
- First Patient Dosed in Phase 2 Trial of ENV105 with Apalutamide to Improve Therapy Sensitivity for Castrate-Resistant Prostate Cancer
- Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study
- Biogen to Discontinue the Development and Commercialization of Aduhelm (aducanumab-avwa)
Clinical trial results archive
- 2024
- January, February, March, April, May
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.